Sort   by:  
 Page size 
UnknownThe effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern.
COVID-19 vaccines are playing a vital role in controlling the COVID-19 pandemic. As SARS-CoV-2 variants encoding mutations in the surface glycoprotein, Spike, continue to emerge, there is increased need to identify immunogens and vaccination regimens that provide the broadest and most durable immune...
S-EPMC9560610 | biostudies-literature
UnknownChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants.
Although the antibody response to COVID-19 vaccination has been studied extensively at the polyclonal level using immune sera, little has been reported on the antibody response at the monoclonal level. Here, we isolate a panel of 44 anti-SARS-CoV-2 monoclonal antibodies (mAbs) from an individual who...
S-EPMC9010245 | biostudies-literature
UnknownEstimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England.

Background

Understanding of the true asymptomatic rate of infection of SARS-CoV-2 is currently limited, as is understanding of the population-based seroprevalence after the first wave of COVID-19 within the UK. The majority of data thus far come from hospitalised patients, with little focus ...
S-EPMC7557299 | biostudies-literature
UnknownAntibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections.
As SARS-CoV-2 variants continue to emerge globally, a major challenge for COVID-19 vaccination is the generation of a durable antibody response with cross-neutralizing activity against both current and newly emerging viral variants. Cross-neutralizing activity against major variants of concern (B.1....
S-EPMC8202432 | biostudies-literature
UnknownNeutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern.
COVID-19 vaccine design and vaccination rollout need to take into account a detailed understanding of antibody durability and cross-neutralizing potential against SARS-CoV-2 and emerging variants of concern (VOCs). Analyses of convalescent sera provide unique insights into antibody longevity and cro...
S-EPMC8556155 | biostudies-literature
UnknownGenomic epidemiology of SARS-CoV-2 in a university outbreak setting and implications for public health planning.
Whole genome sequencing of SARS-CoV-2 has occurred at an unprecedented scale, and can be exploited for characterising outbreak risks at the fine-scale needed to inform control strategies. One setting at continued risk of COVID-19 outbreaks are higher education institutions, associated with student m...
S-EPMC9296497 | biostudies-literature
Sort   by:  
 Page size